First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
Public ClinicalTrials.gov record NCT05527184. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Gynaecological Cancers
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
IIMGN151-1001 is a Phase 1, first in human, open-label dose-escalation, optimization, and expansion study designed to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of IMGN151 in adult participants with recurrent endometrial cancer; recurrent, high-grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers; or recurrent cervical cancers. All participants will be, in the opinion of the investigator, appropriate for nonplatinum single-agent therapy for their next line of therapy.
Study identification
- NCT ID
- NCT05527184
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 256 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 11, 2023 (Actual)
- Primary completion
- Feb 2027 (Estimated)
- Completion
- Feb 2027 (Estimated)
- Last update posted
- Feb 20, 2026
2023 – 2027
United States locations
- U.S. sites
- 32
- U.S. states
- 20
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham /ID# 269045 | Birmingham | Alabama | 35233 | — |
| City of Hope National Medical Center /ID# 269036 | Duarte | California | 91010 | — |
| Moores Cancer Center /ID# 269040 | La Jolla | California | 92037 | — |
| University of California Los Angeles Medical Center /ID# 269037 | Los Angeles | California | 90095 | — |
| Hoag Memorial Hospital Presbyterian /ID# 269047 | Newport Beach | California | 92663 | — |
| UCHSC Anschultz Cancer Pavilion /ID# 269056 | Aurora | Colorado | 80045-2517 | — |
| AdventHealth Celebration /ID# 269030 | Kissimmee | Florida | 34747 | — |
| Mount Sinai Medical Center /ID# 269050 | Miami | Florida | 33140 | — |
| Miami Cancer Institute at Baptist Health /ID# 269041 | Miami | Florida | 33176 | — |
| Florida Cancer Specialists- Sarasota Cattlemen /ID# 269055 | Sarasota | Florida | 34232 | — |
| University of Chicago Medical Center /ID# 269028 | Chicago | Illinois | 60637 | — |
| Massachusetts General Hospital /ID# 278119 | Boston | Massachusetts | 02114 | — |
| Dana-Farber Cancer Institute /ID# 269039 | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Institute - Detroit /ID# 269052 | Detroit | Michigan | 48201 | — |
| University of Mississippi Medical Cancer Center /ID# 269046 | Jackson | Mississippi | 39213 | — |
| Washington University School of Medicine - St. Louis /ID# 269048 | St Louis | Missouri | 63130 | — |
| Holy Name Medical Center /ID# 269051 | Teaneck | New Jersey | 07666 | — |
| Roswell Park Cancer Institute /ID# 269043 | Buffalo | New York | 14263 | — |
| Long Island Jewish Medical Center /ID# 269035 | New Hyde Park | New York | 11040 | — |
| Columbia University Irving Medical Center /ID# 269033 | New York | New York | 10032 | — |
| University of Rochester Medical Center /ID# 269044 | Rochester | New York | 14642 | — |
| University of North Carolina Medical Center /ID# 269027 | Chapel Hill | North Carolina | 27514 | — |
| Atrium Health Levine Cancer Institute /ID# 269049 | Charlotte | North Carolina | 28204 | — |
| The Ohio State University Comprehensive Cancer Center /ID# 269026 | Columbus | Ohio | 43210-1240 | — |
| OU Health - Stephenson Cancer Center /ID# 269025 | Oklahoma City | Oklahoma | 73104 | — |
| University of Pennsylvania /ID# 269042 | Philadelphia | Pennsylvania | 19104 | — |
| West Penn Hospital /ID# 269054 | Pittsburgh | Pennsylvania | 15224-1722 | — |
| Women & Infants Hospital /ID# 269032 | Providence | Rhode Island | 02905 | — |
| Sanford Cancer Center /ID# 269038 | Sioux Falls | South Dakota | 57104 | — |
| Tennessee Oncology Nashville /ID# 269029 | Nashville | Tennessee | 37203 | — |
| MD Anderson Houston /ID# 269057 | Houston | Texas | 77030-4000 | — |
| University of Virginia /ID# 269053 | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05527184, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 20, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05527184 live on ClinicalTrials.gov.